An Advocate-led Study on treatment decisions for those with metastatic HER2+ breast cancer

| Posted on |

Several of our Advocate Collaborative members have helped to design an anonymous survey on treatment choices for individuals with HER2+ metastatic breast cancer, regardless of hormone-receptor status, in the US. This study is being conducted by Drs. Adami and Papautsky at the University of Illinois Chicago and patient advocate, and Advocate Collaborative member, Martha Carlson. Please share with your networks as you see fit.

The survey can be accessed at https://redcap.link/TREAT_HER2.

NOTE: This human subject research study has been reviewed by the Institutional Review Board at the University of Illinois at Chicago and has been determined to be of minimal risk and is exempt. (Protocol 2023-0523)